China Orders New Rules Governing Antibiotics Use Effective Aug. 1
This article was originally published in PharmAsia News
China’s Ministry of Health said it would begin a new policy Aug. 1 proscribing when antibiotics can be prescribed by the nation’s physicians and pharmacies in an effort to prevent overuse.
You may also be interested in...
Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.